Abstract
Mycobacterium tuberculosis presents unique challenges in the peritransplant period. Here, we describe a case of disseminated tuberculosis following renal transplantation with alemtuzumab induction immunosuppression in a patient with remotely treated pulmonary tuberculosis and ongoing risk factors for re-infection. We also review the available literature regarding the prevalence of tuberculosis infection following solid organ transplant and management of high-risk patients, including the role for isoniazid preventative therapy.
2016 BMJ Publishing Group Ltd.
MeSH terms
-
Aged
-
Alemtuzumab
-
Antibodies, Monoclonal, Humanized / adverse effects*
-
Antitubercular Agents / therapeutic use
-
Female
-
Humans
-
Immunosuppression Therapy / adverse effects*
-
Immunosuppressive Agents / adverse effects
-
Isoniazid / therapeutic use*
-
Kidney Transplantation / adverse effects*
-
Mycobacterium tuberculosis*
-
Opportunistic Infections / etiology
-
Opportunistic Infections / microbiology*
-
Opportunistic Infections / prevention & control
-
Tuberculosis / etiology*
-
Tuberculosis / microbiology
-
Tuberculosis / prevention & control
-
Tuberculosis, Miliary / etiology
-
Tuberculosis, Miliary / microbiology
-
Tuberculosis, Miliary / prevention & control
-
Tuberculosis, Pulmonary / drug therapy
-
Tuberculosis, Pulmonary / microbiology
Substances
-
Antibodies, Monoclonal, Humanized
-
Antitubercular Agents
-
Immunosuppressive Agents
-
Alemtuzumab
-
Isoniazid